Drugs / Formosa 1-Breath Free
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06175468 Comparator | Dec 2023 → Apr 2024 | COVID-19, influenza | China Medical University Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Formosa 1-Breath Free | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175468 ↗ |
| Known as | NRICM101 | “After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.” NCT06175468 ↗ |